Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Chromosome instability drives phenotypic switching to metastasis.

Gao C, Su Y, Koeman J, Haak E, Dykema K, Essenberg C, Hudson E, Petillo D, Khoo SK, Vande Woude GF.

Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14793-14798. doi: 10.1073/pnas.1618215113. Epub 2016 Dec 5.

2.

A Developmental and Molecular View of Formation of Auxin-Induced Nodule-Like Structures in Land Plants.

Hiltenbrand R, Thomas J, McCarthy H, Dykema KJ, Spurr A, Newhart H, Winn ME, Mukherjee A.

Front Plant Sci. 2016 Nov 11;7:1692. eCollection 2016.

3.

Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.

Monsma DJ, Cherba DM, Eugster EE, Dylewski DL, Davidson PT, Peterson CA, Borgman AS, Winn ME, Dykema KJ, Webb CP, MacKeigan JP, Duesbery NS, Nickoloff BJ, Monks NR.

Am J Cancer Res. 2015 Mar 15;5(4):1507-18. eCollection 2015.

4.

Disruption of tubular Flcn expression as a mouse model for renal tumor induction.

Chen J, Huang D, Rubera I, Futami K, Wang P, Zickert P, Khoo SK, Dykema K, Zhao P, Petillo D, Cao B, Zhang Z, Si S, Schoen SR, Yang XJ, Zhou M, Xiao GQ, Wu G, Nordenskjöld M, Tauc M, Williams BO, Furge KA, Teh BT.

Kidney Int. 2015 Nov;88(5):1057-69. doi: 10.1038/ki.2015.177. Epub 2015 Jun 17.

PMID:
26083655
5.

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.

Ho TH, Park IY, Zhao H, Tong P, Champion MD, Yan H, Monzon FA, Hoang A, Tamboli P, Parker AS, Joseph RW, Qiao W, Dykema K, Tannir NM, Castle EP, Nunez-Nateras R, Teh BT, Wang J, Walker CL, Hung MC, Jonasch E.

Oncogene. 2016 Mar 24;35(12):1565-74. doi: 10.1038/onc.2015.221. Epub 2015 Jun 15.

6.

Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling.

Foley JM, Scholten DJ 2nd, Monks NR, Cherba D, Monsma DJ, Davidson P, Dylewski D, Dykema K, Winn ME, Steensma MR.

J Transl Med. 2015 Apr 2;13:110. doi: 10.1186/s12967-015-0466-4.

7.

Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations.

Peacock JD, Dykema KJ, Toriello HV, Mooney MR, Scholten DJ 2nd, Winn ME, Borgman A, Duesbery NS, Hiemenga JA, Liu C, Campbell S, Nickoloff BP, Williams BO, Steensma M.

Am J Med Genet A. 2015 Jul;167(7):1429-35. doi: 10.1002/ajmg.a.37048. Epub 2015 Mar 21.

PMID:
25808193
8.

Feasibility of text messaging for ecological momentary assessment of marijuana use in college students.

Phillips MM, Phillips KT, Lalonde TL, Dykema KR.

Psychol Assess. 2014 Sep;26(3):947-57. doi: 10.1037/a0036612. Epub 2014 Apr 21.

PMID:
24749751
9.

Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy.

Xie Q, Su Y, Dykema K, Johnson J, Koeman J, De Giorgi V, Huang A, Schlegel R, Essenburg C, Kang L, Iwaya K, Seki S, Khoo SK, Zhang B, Buonaguro F, Marincola FM, Furge K, Vande Woude GF, Shinomiya N.

Genes Cancer. 2013 Jul;4(7-8):247-60. doi: 10.1177/1947601913501075.

10.

Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.

Andersen NJ, Nickoloff BJ, Dykema KJ, Boguslawski EA, Krivochenitser RI, Froman RE, Dawes MJ, Baker LH, Thomas DG, Kamstock DA, Kitchell BE, Furge KA, Duesbery NS.

Mol Cancer Ther. 2013 Sep;12(9):1701-14. doi: 10.1158/1535-7163.MCT-12-0893. Epub 2013 Jun 26.

11.

CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.

Ooi A, Dykema K, Ansari A, Petillo D, Snider J, Kahnoski R, Anema J, Craig D, Carpten J, Teh BT, Furge KA.

Cancer Res. 2013 Apr 1;73(7):2044-51. doi: 10.1158/0008-5472.CAN-12-3227. Epub 2013 Jan 30.

12.

Evaluation of sex-specific gene expression in archived dried blood spots (DBS).

Resau JH, Ho NT, Dykema K, Faber MS, Busik JV, Nickolov RZ, Furge KA, Paneth N, Jewell S, Khoo SK.

Int J Mol Sci. 2012;13(8):9599-608. doi: 10.3390/ijms13089599. Epub 2012 Aug 2.

13.

Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.

Zhang YW, Staal B, Dykema KJ, Furge KA, Vande Woude GF.

PLoS One. 2012;7(6):e38955. doi: 10.1371/journal.pone.0038955. Epub 2012 Jun 12.

14.

Exome sequencing of liver fluke-associated cholangiocarcinoma.

Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, McPherson JR, Allen GE, Ng CC, Wong BH, Myint SS, Rajasegaran V, Heng HL, Gan A, Zang ZJ, Wu Y, Wu J, Lee MH, Huang D, Ong P, Chan-on W, Cao Y, Qian CN, Lim KH, Ooi A, Dykema K, Furge K, Kukongviriyapan V, Sripa B, Wongkham C, Yongvanit P, Futreal PA, Bhudhisawasdi V, Rozen S, Tan P, Teh BT.

Nat Genet. 2012 May 6;44(6):690-3. doi: 10.1038/ng.2273.

PMID:
22561520
15.

Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.

Gerlinger M, Santos CR, Spencer-Dene B, Martinez P, Endesfelder D, Burrell RA, Vetter M, Jiang M, Saunders RE, Kelly G, Dykema K, Rioux-Leclercq N, Stamp G, Patard JJ, Larkin J, Howell M, Swanton C.

J Pathol. 2012 Jun;227(2):146-56. doi: 10.1002/path.4006. Epub 2012 Apr 18. Erratum in: J Pathol. 2015 Aug;236(4):531.

16.

Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response.

He Y, Xu Y, Zhang C, Gao X, Dykema KJ, Martin KR, Ke J, Hudson EA, Khoo SK, Resau JH, Alberts AS, MacKeigan JP, Furge KA, Xu HE.

Sci Signal. 2011 Jul 5;4(180):ra44. doi: 10.1126/scisignal.2001450.

17.

MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells.

Lee CS, Dykema KJ, Hawkins DM, Cherba DM, Webb CP, Furge KA, Duesbery NS.

PLoS One. 2011 Feb 18;6(2):e17165. doi: 10.1371/journal.pone.0017165.

18.

MK-STYX, a catalytically inactive phosphatase regulating mitochondrially dependent apoptosis.

Niemi NM, Lanning NJ, Klomp JA, Tait SW, Xu Y, Dykema KJ, Murphy LO, Gaither LA, Xu HE, Furge KA, Green DR, MacKeigan JP.

Mol Cell Biol. 2011 Apr;31(7):1357-68. doi: 10.1128/MCB.00788-10. Epub 2011 Jan 24.

19.

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.

Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LF, Richard S, Kahnoski RJ, Anema J, Tuveson DA, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-on W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA.

Nature. 2011 Jan 27;469(7331):539-42. doi: 10.1038/nature09639. Epub 2011 Jan 19. Erratum in: Nature. 2012 Apr 5;484(7392):130.

20.

Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma.

Tan SY, Ooi AS, Ang MK, Koh M, Wong JC, Dykema K, Ngeow J, Loong S, Gatter K, Tan L, Lim LC, Furge K, Tao M, Lim ST, Loong F, Cheah PL, Teh BT.

Leukemia. 2011 Mar;25(3):555-7. doi: 10.1038/leu.2010.295. Epub 2011 Jan 14. No abstract available.

PMID:
21233830
21.

Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas.

Looyenga BD, Furge KA, Dykema KJ, Koeman J, Swiatek PJ, Giordano TJ, West AB, Resau JH, Teh BT, MacKeigan JP.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1439-44. doi: 10.1073/pnas.1012500108. Epub 2011 Jan 10.

22.

Acquiring genome-wide gene expression profiles in Guthrie card blood spots using microarrays.

Khoo SK, Dykema K, Vadlapatla NM, LaHaie D, Valle S, Satterthwaite D, Ramirez SA, Carruthers JA, Haak PT, Resau JH.

Pathol Int. 2011 Jan;61(1):1-6. doi: 10.1111/j.1440-1827.2010.02611.x.

PMID:
21166936
23.

Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.

Klomp JA, Petillo D, Niemi NM, Dykema KJ, Chen J, Yang XJ, Sääf A, Zickert P, Aly M, Bergerheim U, Nordenskjöld M, Gad S, Giraud S, Denoux Y, Yonneau L, Méjean A, Vasiliu V, Richard S, MacKeigan JP, Teh BT, Furge KA.

BMC Med Genomics. 2010 Dec 16;3:59. doi: 10.1186/1755-8794-3-59.

24.

Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing.

Zang ZJ, Ong CK, Cutcutache I, Yu W, Zhang SL, Huang D, Ler LD, Dykema K, Gan A, Tao J, Lim S, Liu Y, Futreal PA, Grabsch H, Furge KA, Goh LK, Rozen S, Teh BT, Tan P.

Cancer Res. 2011 Jan 1;71(1):29-39. doi: 10.1158/0008-5472.CAN-10-1749. Epub 2010 Nov 19.

25.

Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression.

Ang MK, Ooi AS, Thike AA, Tan P, Zhang Z, Dykema K, Furge K, Teh BT, Tan PH.

Breast Cancer Res Treat. 2011 Sep;129(2):319-29. doi: 10.1007/s10549-010-1204-5. Epub 2010 Oct 14.

PMID:
20945089
26.
27.

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R.

Mol Cancer Ther. 2010 Jun;9(6):1525-35. doi: 10.1158/1535-7163.MCT-09-1106. Epub 2010 May 25.

28.

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.

Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA.

Nature. 2010 Jan 21;463(7279):360-3. doi: 10.1038/nature08672. Epub 2010 Jan 6.

29.

Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.

Schaeffer EM, Guzzo TJ, Furge KA, Netto G, Westphal M, Dykema K, Yang X, Zhou M, Teh BT, Pavlovich CP.

BJU Int. 2010 Jul;106(1):62-5. doi: 10.1111/j.1464-410X.2009.09139.x. Epub 2009 Dec 11.

30.

Repeated hepatocyte growth factor neutralizing antibody treatment leads to HGF/SF unresponsiveness in human glioblastoma multiforme cells.

Zhao P, Gao C, Dykema K, Furge K, Feng Z, Cao B.

Cancer Lett. 2010 May 28;291(2):209-16. doi: 10.1016/j.canlet.2009.10.014. Epub 2009 Nov 11.

PMID:
19910109
31.

Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.

Qian CN, Furge KA, Knol J, Huang D, Chen J, Dykema KJ, Kort EJ, Massie A, Khoo SK, Vanden Beldt K, Resau JH, Anema J, Kahnoski RJ, Morreau H, Camparo P, Comperat E, Sibony M, Denoux Y, Molinie V, Vieillefond A, Eng C, Williams BO, Teh BT.

Cancer Res. 2009 Nov 1;69(21):8256-64. doi: 10.1158/0008-5472.CAN-09-1689. Epub 2009 Oct 20.

32.

Molecular signatures reveal circadian clocks may orchestrate the homeorhetic response to lactation.

Casey T, Patel O, Dykema K, Dover H, Furge K, Plaut K.

PLoS One. 2009 Oct 9;4(10):e7395. doi: 10.1371/journal.pone.0007395.

33.

5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.

Eisenmann KM, Dykema KJ, Matheson SF, Kent NF, DeWard AD, West RA, Tibes R, Furge KA, Alberts AS.

Oncogene. 2009 Oct 1;28(39):3429-41. doi: 10.1038/onc.2009.207. Epub 2009 Jul 13. Review.

PMID:
19597464
34.

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12909-14. doi: 10.1073/pnas.0810403106. Epub 2009 Jun 30.

35.

The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development.

Lindvall C, Zylstra CR, Evans N, West RA, Dykema K, Furge KA, Williams BO.

PLoS One. 2009 Jun 5;4(6):e5813. doi: 10.1371/journal.pone.0005813.

36.

A highly invasive human glioblastoma pre-clinical model for testing therapeutics.

Xie Q, Thompson R, Hardy K, DeCamp L, Berghuis B, Sigler R, Knudsen B, Cottingham S, Zhao P, Dykema K, Cao B, Resau J, Hay R, Vande Woude GF.

J Transl Med. 2008 Dec 3;6:77. doi: 10.1186/1479-5876-6-77.

37.

Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.

Chen J, Futami K, Petillo D, Peng J, Wang P, Knol J, Li Y, Khoo SK, Huang D, Qian CN, Zhao P, Dykema K, Zhang R, Cao B, Yang XJ, Furge K, Williams BO, Teh BT.

PLoS One. 2008;3(10):e3581. doi: 10.1371/journal.pone.0003581. Epub 2008 Oct 30. Erratum in: PLoS ONE. 2008;3(11). doi: 10.1371/annotation/0f06471c-1993-4144-b785-d58924ac0b5c. PLoS ONE. 2008;3(11). doi: 10.1371/annotation/136385d5-b241-4ecc-b31a-6dea3ebf3bc4. Dykyma, Karl [corrected to Dykema, Karl].

38.

Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response.

Koeman JM, Russell RC, Tan MH, Petillo D, Westphal M, Koelzer K, Metcalf JL, Zhang Z, Matsuda D, Dykema KJ, Houseman HL, Kort EJ, Furge LL, Kahnoski RJ, Richard S, Vieillefond A, Swiatek PJ, Teh BT, Ohh M, Furge KA.

PLoS Genet. 2008 Sep 5;4(9):e1000176. doi: 10.1371/journal.pgen.1000176. Erratum in: PLoS Genet. 2008 Jul;4(7). doi: 10.1371/annotation/7f57058f-cc02-45a6-bfab-a835619e3916.

39.

Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation.

Bonte D, Lindvall C, Liu H, Dykema K, Furge K, Weinreich M.

Neoplasia. 2008 Sep;10(9):920-31.

40.

Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma.

Furge KA, Dykema K, Petillo D, Westphal M, Zhang Z, Kort EJ, Teh BT.

Can Urol Assoc J. 2007 Jun;1(2 Suppl):S21-7.

41.

Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature.

Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, Furge KA, Comperat EM, Lae M, Bouvier R, Boccon-Gibod L, Denoux Y, Ferlicot S, Forest E, Fromont G, Hintzy MC, Laghouati M, Sibony M, Tucker ML, Weber N, Teh BT, Vieillefond A.

Am J Surg Pathol. 2008 May;32(5):656-70. doi: 10.1097/PAS.0b013e3181609914.

PMID:
18344867
42.

Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations.

Gao C, Furge K, Koeman J, Dykema K, Su Y, Cutler ML, Werts A, Haak P, Vande Woude GF.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):8995-9000. Epub 2007 May 15.

43.

Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma.

Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, Lucin K, Kahnoski R, Yang XJ, Teh BT.

Cancer Res. 2007 Apr 1;67(7):3171-6.

44.

Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling.

Furge KA, Tan MH, Dykema K, Kort E, Stadler W, Yao X, Zhou M, Teh BT.

Oncogene. 2007 Feb 26;26(9):1346-50. Review.

PMID:
17322920
45.

Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma.

Patil MA, Gütgemann I, Zhang J, Ho C, Cheung ST, Ginzinger D, Li R, Dykema KJ, So S, Fan ST, Kakar S, Furge KA, Büttner R, Chen X.

Carcinogenesis. 2005 Dec;26(12):2050-7. Epub 2005 Jul 6.

PMID:
16000397
47.
48.

Calculation of some integrals for the atomic three-electron problem.

King FW, Dykema KJ, Lund AD.

Phys Rev A. 1992 Nov 1;46(9):5406-5416. No abstract available.

PMID:
9908788

Supplemental Content

Loading ...
Support Center